2003•PubMedRequires access

Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.

Giulio Trapè, Luana Fianchi, Marco Lai, Luca Laurenti, Roberta Piscitelli, Giuseppe G.M. Leone, Livio Pagano

Abstract

We administered rituximab monoclonal antibody to five patients suffering from a lymphoproliferative CD20-positive disease associated, at diagnosis or after starting treatment, with autoimmune hemolytic anemia (AIHA). After treatment with rituximab we observed an improvement of AIHA in all cases, and, in one case, improvement of the autoimmune thrombocytopenia associated with the AIHA. There were no relevant side effects.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 33 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rituximab, Autoimmune hemolytic anemia, Medicine, Lymphoproliferative disorders, CD20, Immunology, Monoclonal antibody, Monoclonal